Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines

Radiotherapy and Oncology

Volumn 79, Issue 3, 2006, Pages 270-277

  Girinsky, Theodore ^a   van der Maazen, Richard ^b   Specht, Lena ^c   Aleman, Berthe ^d   Poortmans, Philip ^e   Lievens, Yolande ^f   Meijnders, Paul ^b   Ghalibafian, Mithra ^a   Meerwaldt, Jacobus ^g   Noordijk, Evert ^h  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Department of Radiotherapy ^*  (Belgium)

^c FINSEN LABORATORY   (Denmark)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e DR BERNARD VERBEETEN INSTITUTE   (Netherlands)

^f Radiotherapy Department   (Belgium)

^g MEDISCH SPECTRUM TWENTE   (Netherlands)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Combined modality treatment; Hodgkin lymphoma; Involved field radiation treatment; Involved node radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; EARLY CANCER; HODGKIN DISEASE; HUMAN; INVOLVED NODE RADIOTHERAPY; LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIOTHERAPY;

COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; EUROPE; HODGKIN DISEASE; HUMANS; LYMPH NODES; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; RADIOTHERAPY, CONFORMAL;

EID: 33746346422     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2006.05.015     Document Type: Article

References (14)

1. Aleman B.M., van den Belt-Dusebout A.W., Klokman W.J., et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21 (2003) 3431-3439
2. Bhatia S., Robison L., L Oberlin O., et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 334 (1996) 745-751
3. Brincker H., and Bentzen S.M. A re-analysis of available dose -response and time-dose data in Hodgkin's disease. Radiother Oncol 30 (1994) 227-230
4. Diehl V., Brillant C., Engert A., et al. HD10: Investigating reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma. Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG) [Abstract]. J Clin Oncol 23 (2005) 16S-561S
5. Engert A., Schiller P., Josting A., et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavourable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21 (2003) 3601-3608
6. Ferme C, Eghbali H, Hagenbeek A, et al. MOPP/ABV hybrid and irradiation in unfavorable supradiaphragmatic clinical stages I-II Hodgkin's disease. Comparison of three treatment modalities. Preliminary results of the EORTC-GELA H8U randomized trial in 995 patients. Blood. 2000; 96: A576.
7. Hancock S.L., Tucker M.A., and Hoppe R.T. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. J Am Med Assoc 270 (1993) 1949-1955
8. ICRU. Prescribing, recording and reporting photon beam therapy. Report 50, International Commission on Radiation Units and Measurements. Washington, DC, 1993.
9. Koontz B, Kirkpatrick J, Clough R, et al: Combined modality therapy versus radiotherapy alone for treatment of early stage Hodgkin disease: cure versus complications. J Clin Oncol 2005;24:605-11.
10. Mauch P. Second malignancies after curative radiation therapy for good prognosis cancers. Int J Radiat Oncol Biol Phys 33 4 (1995) 959-960
11. Ng K., Bernardo M.P., Weller E., et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 20 (2002) 2101-2108
12. Noordijk E.M., Thomas J., Ferme C., et al. First results of the EORTC-GELA randomized trials: the H9-F trial (comparing 3 radiation dose levels) and the H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL).[Abstract]. J Clin Oncol 23 (2005) 16S-561S
13. Shahidi M., Kamangari N., Ashley S., et al. Site of relapse after chemotherapy alone in stage I and II Hodgkin's disease. Radiother Oncol 78 (2006) 1-5
14. van Leeuwen F.E., Klokman W.J., Stovall M., et al. Role of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 95 (2000) 971-980